Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 210

1.

Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.

Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B, Delemer B, Ciccarelli E, Beck-Peccoz P, Caron P, Daly AF, Beckers A.

Eur J Endocrinol. 2012 Nov;167(5):651-62. doi: 10.1530/EJE-12-0236. Epub 2012 Aug 23. Erratum in: Eur J Endocrinol. 2012 Dec;167(6):887.

PMID:
22918301
[PubMed - indexed for MEDLINE]
Free Article
2.

Giant prolactinomas in men: efficacy of cabergoline treatment.

Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.

Clin Endocrinol (Oxf). 2003 May;58(5):662-70.

PMID:
12699451
[PubMed - indexed for MEDLINE]
3.

Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.

Delgrange E, Daems T, Verhelst J, Abs R, Maiter D.

Eur J Endocrinol. 2009 May;160(5):747-52. doi: 10.1530/EJE-09-0012. Epub 2009 Feb 17.

PMID:
19223454
[PubMed - indexed for MEDLINE]
Free Article
4.

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.

Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.

Clin Endocrinol (Oxf). 2000 Jul;53(1):53-60.

PMID:
10931080
[PubMed - indexed for MEDLINE]
5.

Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.

Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T.

Pituitary. 2000 May;2(4):277-81.

PMID:
11081149
[PubMed - indexed for MEDLINE]
6.

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.

J Clin Endocrinol Metab. 1997 Mar;82(3):876-83.

PMID:
9062500
[PubMed - indexed for MEDLINE]
7.

Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.

J Clin Endocrinol Metab. 1997 Nov;82(11):3574-9.

PMID:
9360509
[PubMed - indexed for MEDLINE]
8.

Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.

Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F.

J Endocrinol Invest. 1999 May;22(5):354-9.

PMID:
10401709
[PubMed - indexed for MEDLINE]
9.

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.

Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.

Eur J Endocrinol. 2008 May;158(5):595-603. doi: 10.1530/EJE-07-0806.

PMID:
18426817
[PubMed - indexed for MEDLINE]
Free Article
10.

Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.

Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.

J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61.

PMID:
11701688
[PubMed - indexed for MEDLINE]
11.

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.

Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.

J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52.

PMID:
10852458
[PubMed - indexed for MEDLINE]
12.

Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.

Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K.

J Clin Endocrinol Metab. 2008 Dec;93(12):4721-7. doi: 10.1210/jc.2007-2758. Epub 2008 Sep 23.

PMID:
18812485
[PubMed - indexed for MEDLINE]
13.

Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.

Primeau V, Raftopoulos C, Maiter D.

Eur J Endocrinol. 2012 May;166(5):779-86. doi: 10.1530/EJE-11-1000. Epub 2012 Feb 2.

PMID:
22301915
[PubMed - indexed for MEDLINE]
Free Article
14.

Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.

N Engl J Med. 2003 Nov 20;349(21):2023-33.

PMID:
14627787
[PubMed - indexed for MEDLINE]
Free Article
15.

Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.

Shimon I, Benbassat C, Hadani M.

Eur J Endocrinol. 2007 Feb;156(2):225-31.

PMID:
17287412
[PubMed - indexed for MEDLINE]
Free Article
16.

The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.

Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.

Pol Arch Med Wewn. 2003 May;109(5):489-95.

PMID:
14768178
[PubMed - indexed for MEDLINE]
17.

The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.

Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M.

Clin Endocrinol (Oxf). 1996 Jun;44(6):711-6.

PMID:
8759184
[PubMed - indexed for MEDLINE]
18.

Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.

Delgrange E, Duprez T, Maiter D.

Clin Endocrinol (Oxf). 2006 Apr;64(4):456-62. Erratum in: Clin Endocrinol (Oxf). 2006 May;64(5):602.

PMID:
16584520
[PubMed - indexed for MEDLINE]
19.

Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.

Kawabata Y, Ueno Y, Horikawa F, Miyake H, Miki N, Ono M.

Surg Neurol. 2008 Jan;69(1):85-8; discussion 88. Epub 2007 Oct 29.

PMID:
17967478
[PubMed - indexed for MEDLINE]
20.

Effect of dopaminergic drug treatment on surgical findings in prolactinomas.

Menucci M, Quiñones-Hinojosa A, Burger P, Salvatori R.

Pituitary. 2011 Mar;14(1):68-74. doi: 10.1007/s11102-010-0261-4.

PMID:
20878243
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk